However, managing treatment-resistant depression often requires ... or oral tablets. “In our center, we’ve seen really ...

I specialize in helping individuals with treatment-resistant depression (TRD) by offering Spravato (esketamine) therapy, an FDA-approved breakthrough treatment that provides new hope for those ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

There’s also the chance it could be misused. Because of this, Spravato is only available at certified treatment centers where patients are closely monitored. You won’t be able to pick it up at ...

Meaning, you have to go to a specialty treatment center and use the medication under the supervision of a licensed healthcare provider. After you take Spravato, you have to be observed for at ...

That is one of 3,000 outpatient treatment centers in the U.S. that are certified to administer Spravato, according to J&J's tally. Mattingly said patients can now choose to take Spravato with or ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...

Spravato is made from esketamine ... and misuse," so it will continue to be administered in certified treatment centers. Major depressive disorder affects more than 20 million adults in the U.S. About ...

Spravato had been cleared in the United States in 2019 to be used together with an oral antidepressant for both treatment-resistant depression and for people with MDD. Related Trump announces $500 ...